# Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI

> **NCT06602622** · PHASE4 · RECRUITING · sponsor: **Instituto Mexicano del Seguro Social** · enrollment: 108 (estimated)

## Conditions studied

- HIV
- HIV Associate Weight Loss
- HIV-1 Infection
- Integrase Inhibitors, HIV; HIV PROTEASE INHIB
- Weight Change
- Weight Loss

## Interventions

- **DRUG:** Integrase inhibitor
- **DRUG:** Doravirine + tenofovir DF + lamivudine

## Key facts

- **NCT ID:** NCT06602622
- **Lead sponsor:** Instituto Mexicano del Seguro Social
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-14
- **Primary completion:** 2025-11-14
- **Final completion:** 2025-11-14
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06602622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06602622, "Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06602622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*